Genetic modifier of Friedreich's ataxia points toward treatment for devastating disorder

Friedreich's ataxia (FA) is a rare but devastating genetic disorder. Those with the condition are often diagnosed between 5 ...
Le Lézard

Ensoma Announces Clearance of U.K. Clinical Trial Authorization Application for EN-374, First In Vivo HSC-Directed Gene Insertion Therapy

Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced U.K. Medicines and Healthcare Products Regulatory Agency ...

UPDATE -- Tessera Therapeutics Announces Chief Financial Officer (CFO) Transition and Appointment of Kathy Bergsteinsson as CFO

Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced a planned leadership transition in its executive team. Howard ...
Le Lézard

Mice Model Market Trends and Growth Opportunities by Segment & Region 2025-2032 - Transformative Innovations in Genetic Engineering Propel Mice Model Research in Oncology and ...

The "Mice Model Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. The mice model market is experiencing robust growth, with projected expansion from USD 1.61 ...